Applied Materials, Inc. (NASDAQ: AMAT) — The Value Name in a Bubble, Which Still Isn’t Value

Independent Research — Wafer-Fabrication Equipment & Materials Engineering

Report date: June 10, 2026 | Price (2026-06-09): $499.21 | Market cap: ~$396B | Enterprise value: ~$392B Fiscal year-end: late October | Shares outstanding: ~794M (diluted ~799M)

Standing note: the analysis below (Sections 1–15) is deliberately written without a buy/sell recommendation and without a price target. The single exception is the Claude’s Take block immediately below, which is the author’s own independent opinion. This article is general information, not investment advice.

⚡ Claude’s Take

This block is the author’s own independent opinion. It is general information, not investment advice. The analysis that follows (Sections 1–15) carries no recommendation and no price target.

Verdict: HOLD / own the business, respect the price. The cheapest of the WFE majors, but “cheapest” here means a 99th-percentile own-history multiple on near-peak-cycle earnings. AVOID as fresh money at $499 (~31× forward / ~47× trailing); accumulate with conviction on a genuine cyclical washout — roughly the $300–360 zone (~18–22× a normalized ~$16–18 mid-cycle non-GAAP EPS). Not a short: the franchise is too good and the up-cycle too live. Tag: “The value name in a bubble — which still isn’t value.”

Applied Materials is the broadest, and in many ways the best-positioned, of the wafer-fab-equipment oligopolists: the #1 supplier in deposition, epitaxy, ion implant, thermal and CMP, the #1 in conductor etch for both gate-all-around logic and DRAM, and the clear leader in advanced packaging — a materials-engineering franchise no competitor can replicate in breadth. It throws off ~50% gross margins, ~32% non-GAAP operating margins, ~40% ROE, ~$5.7B of free cash flow, and returns ~100%+ of it while shrinking the share count and raising the dividend at a double-digit clip from a net-cash balance sheet. The quality is not in question. The interesting fact is the relative price: at ~31× forward earnings AMAT is conspicuously cheaper than Lam (41×), KLA (43×) and ASML (37×) — the rare case where the highest-quality-by-breadth name is also the cheapest in its peer set. That discount is real and is the bull’s best argument.

But “cheap vs. peers” is not the same as “cheap.” On its own ten-year history AMAT trades at the 99.9th percentile of P/E, P/B and P/S simultaneously — a stock that spent most of the last decade at 12–18× earnings now sits at 47× trailing, and the earnings it is being applied to are running at management’s own description of “most leading-edge logic and DRAM fabs running at full capacity.” That is the classic cyclical trap: a peak multiple on near-peak earnings. The market is underwriting that AI capex has flattened the semiconductor capital cycle — WFE growing 30%+ in 2026, another record in 2027, China and ICAPS troughing rather than structurally eroding. Some of that is probably right (the AI build is real and AMAT’s mix has genuinely shifted toward the best parts of WFE). What I distrust is the combination of peak cycle, peak multiple, and a China business (still ~24–30% of revenue) being slowly in-sourced by subsidized domestic competitors while a $253M export-controls settlement and serial DOJ/BIS subpoenas sit in the footnotes. Conviction: medium. The peer-relative discount keeps me from the “avoid”/short camp that I’d apply to Lam at its 99.9th percentile; the absolute own-history multiple on cyclical-peak earnings keeps me from buying here. Flips bullish on a WFE digestion that resets the entry into the low-$300s with the franchise intact, or hard evidence the AI-capex cycle has genuinely de-risked the trough. Flips bearish if China revenue falls off a cliff (controls + domestic substitution) while the multiple is still north of 35×, or if a memory/AI-capex air-pocket prints WFE down year-over-year. Best house on a frothy street — but it’s still the same street.

1. Executive Summary

Applied Materials is the largest supplier of wafer-fabrication equipment (WFE) in the world and the only one that competes across nearly the entire materials-engineering stack — the deposition, epitaxy, etch, implant, thermal-processing, planarization (CMP), packaging and inspection steps that physically build a transistor and its interconnect, layer by layer. It deliberately cedes only lithography (ASML’s monopoly) and trails one rival (KLA) in process control. FY2025 revenue was $28.37B, split ~73% Semiconductor Systems (new tools) and ~23% Applied Global Services (AGS — the installed-base services-and-spares annuity), with the balance display and other. Against this, the stock at $499 carries a ~$396B market capitalization.

The business quality is well-evidenced in the financials. Non-GAAP gross margin reached 50.0% in Q2 FY26 — the highest in more than 25 years — non-GAAP operating margin 32.1%, return on equity ~40%, and free cash flow ~$5.7B in FY2025 even after capex doubled to fund a new R&D platform. The balance sheet is net cash. Capital allocation is disciplined and shareholder-friendly: a $20B buyback authorization ($13.2B remaining), repurchases that have climbed from $2.2B (FY23) to $4.9B (FY25), a dividend raised 15% in March 2026 (the eighth straight double-digit raise) at only a ~20% payout, and a diluted share count reduced from ~919M (FY21) to ~799M — all funded from cash flow, not leverage. Management is paid against an economic-profit (ROIC-vs-WACC) and relative-TSR scorecard, and the only sizeable M&A attempt of the era (the ~$2.2B Kokusai Electric deal) was walked away from in 2023 rather than fight Chinese antitrust — a point in favor of discipline.

The industry is among the best-structured in technology: a concentrated, rational, non-overlapping oligopoly (Applied, ASML, Lam, Tokyo Electron, KLA control ~65%+ of front-end equipment), with formidable barriers to entry (multi-year customer qualification, decades of process IP, an installed-base service flywheel, ~$3.6B/yr of R&D) and a genuine secular tailwind: as the industry goes “3D” — gate-all-around transistors, backside power, 3D DRAM, HBM and advanced packaging — the deposition/etch/materials-engineering intensity per wafer rises, expanding Applied’s served market faster than WFE overall. Management frames AI infrastructure as driving leading-edge foundry-logic, DRAM and advanced packaging to >80% of 2026 WFE growth — precisely Applied’s strongest lanes — and guides its systems business to grow >30% in calendar 2026, AGS to mid-teens, and packaging revenue >50%.

Two structural caveats temper the quality. First, deep cyclicality: WFE downturns are sharp and Applied swings with them; the current up-leg has fabs “running at full capacity,” which is what a cyclical peak looks like from the inside. Second, China (~30% of FY25 revenue, falling from a 37% FY24 peak): a trailing-node/ICAPS-heavy base structurally eroding as US export controls cap leading-edge sales and state-subsidized domestic toolmakers (NAURA, AMEC, ACM, Piotech) in-source Applied’s deposition/etch/CMP lanes — with a $253M export-controls settlement and multiple DOJ/BIS/SEC subpoenas as the visible cost.

The entire tension sits in valuation. At ~47× trailing and ~31× forward earnings, AMAT is simultaneously the cheapest WFE major cross-sectionally and at the 99.9th percentile of its own ten-year multiple history. Embedded-expectations analysis implies the market is underwriting a durable, AI-driven WFE up-cycle with no deep digestion and a China trough rather than a structural decline. Our scenario work is asymmetric: in the base case, earnings grow materially yet the stock returns little as the multiple normalizes; only an uninterrupted super-cycle produces an attractive return. The franchise is correctly understood as wide-moat; the cyclicality and the multiple, in our reading, are where the risk lives.

2. Business Overview

What Applied does. Applied Materials sells the equipment, services and software that semiconductor manufacturers use to fabricate integrated circuits. Its self-description — “materials engineering solutions” — is precise: where ASML owns the patterning (lithography) step and KLA owns seeing defects (process control), Applied owns the largest share of the steps that physically add, remove, modify and planarize the atomic-scale films and structures on a wafer. Its product families span epitaxy (Centura/epi), chemical and physical vapor deposition (CVD/PVD), atomic-layer deposition (ALD — e.g., the new Trillium metal-gate platform), plasma-enhanced CVD (the new Precision PECVD for shallow-trench isolation), conductor etch (the Sym3/Sym3 Z platform, “the fastest-ramping product in Applied’s history”), ion implantation, rapid thermal processing, chemical-mechanical planarization (CMP), advanced packaging (3D stacking, hybrid bonding, the pending NEXX panel-level acquisition), and process diagnostics & control (eBeam/optical inspection — its weakest lane). (Source: FY2025 10-K, Item 1; Q2 FY26 earnings call, 2026-05-14.)

How it makes money — two segments plus a third leg. Applied reports two segments and a corporate bucket:

(Source: FY2025 10-K MD&A; FY2023 10-K. Note: effective Q1 FY26 the 200mm equipment business was recast from AGS into SSG, raising SSG’s share and modestly trimming AGS — relevant when comparing FY26 segment optics to history.)

Semiconductor Systems is the cyclical heart — the new etch/deposition/implant/CMP tools customers buy when they build or upgrade a fab. Its segment operating margin is consistently strong: 36.0% (FY23) → 35.1% (FY24) → 35.5% (FY25), and in Q2 FY26 SSG posted a 54.8% gross margin (the new segment-level disclosure), the structural reason company gross margin hit 50%. SSG end-market mix is dominated by foundry-logic (67% of SSG in FY25), then DRAM (26%), then NAND (a small 7%). Within foundry-logic, the split between leading-edge (≤7nm/GAA) and ICAPS — Applied’s term for the non-leading-edge IoT, Communications, Auto, Power and Sensor nodes — matters: 2026 is the first year in several where leading-logic spend exceeds ICAPS.

Applied Global Services is the quality/annuity layer: spares, field service, equipment-productivity software and 200mm/legacy support sold against an installed base with more than 35,000 chambers connected to Applied’s proprietary “AIx” software. AGS revenue rose to a record $1.67B in Q2 FY26 (+17% YoY), carries ~28–29% operating margins, and is far less cyclical than systems because it is driven by factory utilization rather than new-capacity decisions. Management has raised the AGS multi-year growth target to mid-teens and is trying to shift more of it to subscription agreements — an aspiration, not yet a contractual lock (much remains transactional spares/service). AGS backlog was $7.1B at FY25 year-end, ~48% of total backlog. (Source: FY2025 10-K; Q2 FY26 call, Dickerson/Hill.)

Geography and customer concentration. Applied’s revenue is overwhelmingly international, and the regional mix is itself a window into the cycle and the China problem. FY25 revenue by region: China $8.53B (30%), Taiwan $6.86B (24%), Korea $5.61B (20%), Japan $2.27B (8%), US $3.06B (11%), Europe $0.96B (3%). The year-on-year swings are large and informative — China fell from a 37% peak in FY24 (when trailing-node “pull-forward” buying surged ahead of tightening export controls) to 30% in FY25, while Taiwan jumped (TSMC’s leading-edge/AI build) and Korea rose (DRAM/HBM). This is the AI-driven mix shift visible in geography: spending rotating out of Chinese trailing nodes and into Taiwanese/Korean leading-edge and memory. Customer concentration is high and structural to WFE: the two largest customers were ~19% and ~15% of FY25 revenue (~21% and ~15% in H1 FY26), and in FY23 the named top three were TSMC (19%), Samsung (15%) and Intel (10%). The entire leading-edge buyer universe is a handful of names — TSMC, Samsung, SK Hynix, Micron, Intel — so concentration is unavoidable, and it is rising as AI capex skews toward TSMC. (Source: FY2025 10-K geographic and customer disclosure; Q2 FY26 10-Q.)

Why the architecture is better than a commodity equipment vendor. Two features distinguish Applied. First, breadth and co-optimization: it is the only WFE vendor spanning nearly all materials-engineering steps, which lets it co-develop integrated solutions across deposition + etch + implant + CMP + packaging — a capability no single-lane competitor can match, and the source of its “value-based pricing.” Second, the installed-base annuity: each system sold seeds decades of AGS spares, service and software revenue, so the company continually builds a larger, more stable float beneath the cyclical systems business. The combination captures both the cyclical upside of new-fab spending and a growing services annuity — a higher-quality revenue architecture than the “equipment maker” label implies.

Verdict (Business Overview). Applied is the broadest, highest-content franchise in WFE — a cyclical systems engine (73% of revenue, ~35% margins) plus a utilization-linked services annuity (23%, ~29% margins) plus a small display/corporate leg — with genuine pricing power now visible in a 50% gross margin. The breadth is the structural advantage; the customer/geographic concentration and the cyclicality of systems are the features that keep it firmly cyclical.

3. Industry Dynamics

Market structure and size. Wafer-fabrication equipment is large, concentrated and structurally attractive. SEMI pegs WFE near ~$116B in 2025 and ~$135–140B in 2026, with total semiconductor equipment (including back-end/test) at a record ~$139B in 2026 and ~$156B in 2027. Applied’s own framing on the Q2 FY26 call is that WFE is growing in 2026 with leading-edge foundry-logic, DRAM and advanced packaging accounting for >80% of the year-on-year growth — and that 2027 will be “another strong, record year.” The “>$100B WFE” that was an aspiration is now the floor, and AI capex has lifted growth from the historical ~8–10% trend into 20–30%+ up-years. (Source: SEMI 2025/2026; Q2 FY26 call.)

A rational, segmented oligopoly. The top five — Applied Materials, ASML, Lam Research, Tokyo Electron, KLA — control roughly 65%+ of front-end equipment, and the structure is unusually good because the leaders are non-overlapping by tool type: ASML owns EUV lithography outright; TEL holds ~88–90% of coat/develop; KLA ~50%+ of inspection/metrology; Lam leads etch and 3D-NAND deposition; Applied leads the broad materials-engineering middle — deposition, epitaxy, implant, thermal, CMP, and now conductor etch for GAA and DRAM. Because the players rarely attack each other’s strongholds head-on, rivalry is rational: there is no price war, and industry gross margins have risen (Applied’s non-GAAP gross margin is up ~800bps since 2013), the signature of pricing power in a disciplined supply structure. In Greenwald’s framework these are economies-of-scale plus customer-captivity moats operating in narrowly-defined relevant markets (a specific process step at a specific customer node). (Source: FY2025 10-K Competition; investment-research-frameworks skill.)

Value chain and profit pools. The chain runs from EDA/IP (Synopsys, Cadence) through fabless design (NVIDIA, AMD, Apple) to manufacturing (foundries TSMC/Samsung; IDMs Intel/Micron/SK Hynix), with the equipment and materials vendors selling the “picks and shovels” into the manufacturing layer. Two features make the equipment slice attractive. First, it is diversified across end-customers: Applied sells to every leading-edge manufacturer regardless of which fabless designer or end-application (AI, mobile, auto) ultimately wins — it is levered to total industry capacity, not to any single chip architecture. Second, the profit pool is concentrated and defended: each niche is a near-monopoly or tight oligopoly, so the equipment makers capture a disproportionate, rising share of the manufacturing-layer profit pool. The embedded risk is the flip side: equipment sits downstream of the capex decision, so when manufacturers collectively pause (a memory glut, an AI-demand digestion), the equipment layer absorbs the full amplitude with a lag — the cyclicality is structural to the value-chain position.

The SAM-expansion tailwind — Applied’s specific edge. The industry “going 3D” raises materials-engineering intensity at every inflection, and Applied’s breadth means it captures content across more of them than any peer:

• Gate-all-around (GAA) transistors require more deposition, epitaxy and selective-etch steps than FinFET; Applied says GAA “grows our available market considerably while providing a catalyst for multiple points of market share gains,” anchored by the new Trillium ALD (metal gate) and Precision PECVD (STI) platforms.
• Advanced packaging / heterogeneous integration (HBM, 3D chiplet stacking, hybrid bonding) is where Applied calls itself “the overall leader”; it guides packaging revenue >50% in CY2026 and is acquiring NEXX for panel-level capability.
• DRAM (6F²→4F²→eventual 3D-DRAM) plays to Applied’s strength in wiring, patterning and peripheral logic; it claims it is the #1 process-equipment provider in memory today and expects to gain DRAM share at upcoming architecture inflections.

Cycle position and amplitude. Where 2026 sits in the cycle is the whole valuation question. WFE historically runs roughly one down-year followed by ~three up-years, and amplitude is large (the CY2023 memory-led downturn cut memory capex ~19%, with individual makers down 40–50%). We are now in a strong up-leg that management characterizes as supply-constrained — “most leading-edge logic and DRAM fabs are running at full capacity,” with the binding constraint cleanroom space, and “the clearest and longest visibility we’ve ever had.” The critical analytical point: constrained supply at the top of an up-leg is not evidence the cycle has been abolished — it is what every cyclical peak looks like from the inside. Management’s “secular growth … here for a good amount of time” framing is precisely the confident language the capital-cycle framework teaches one to distrust at booms.

Demand drivers, quantified. The AI build is not a vague tailwind; it has specific, measurable transmission channels into Applied’s revenue. Leading-edge foundry-logic (GAA + the AI-accelerator die at TSMC/Samsung/Intel) drives the largest single block of incremental WFE and is content-rich for Applied’s epi/deposition/etch/implant. DRAM/HBM is the second engine: HBM stacks (used in every AI accelerator) are intensely 3D and TSV-oriented, and DRAM capex is forecast to grow double-digits as makers add 6F² capacity and develop next-generation architectures — Applied calls itself #1 in memory process equipment and expects DRAM share gains at each inflection. Advanced packaging (HBM integration, 3D chiplet stacking, hybrid bonding) is the third and fastest engine — guided >50% growth in CY2026. NAND, by contrast, remains the laggard (a small 7% of SSG), with limited new-wafer-start demand. The composition matters: Applied’s exposure is now weighted to the three highest-growth, highest-content end-markets and away from the cyclically-depressed NAND and the geopolitically-capped Chinese ICAPS — a genuinely better demand book than it had two years ago, even before the cycle question.

Capital-cycle read (Marathon). The equipment supply side is disciplined and concentrated (Applied is capex-light at ~8% of revenue even with its current build), which genuinely justifies a structurally higher multiple than a commodity-cyclical deserves. But the warning signs Marathon watches for are emerging on the customer side: record fab capex, 30%+ WFE growth, management “as optimistic as you’ve ever heard,” capacity justified by AI-demand forecasts. Because the oligopoly is nearly impossible to enter, mean reversion will come not from new equipment competitors but from the demand cycle turning — historically a sharp event. The favorable supply structure and the elevated demand-cycle position are both true at once; conflating them (using the former to dismiss the latter) is the central error the bull case risks.

Regulation — the structural double-edge. US/Dutch/Japanese export controls bar leading-edge tool sales to restricted Chinese fabs. This protects the most valuable slice of Applied’s market by freezing Chinese competitors out of the global leading edge — but it accelerates domestic substitution at the trailing edge, where Chinese fabs that cannot buy foreign leading-edge tools (and face localization mandates) redirect spend to local vendors. For Applied, whose China business is ICAPS/trailing-node-heavy, that is the worse end of the trade.

Verdict (Industry): STRUCTURALLY GOOD — among the best-structured industries in technology — but cyclical and currently at an elevated, AI-driven point in the demand cycle. Genuine barriers to entry, rational non-overlapping competition, rising margins, and a 3D tailwind that disproportionately favors Applied’s broad materials-engineering franchise. Two non-negotiable caveats: deep cyclicality, and a China position more exposed to trailing-node substitution than any peer.

4. Competitive Position

The moat, named. Applied’s competitive advantage is best described in Greenwald’s taxonomy as economies of scale (in R&D and installed base) reinforced by customer captivity (process requalification cost), expressed through the widest product portfolio in the industry. The mechanism:

1. R&D scale. Applied spent $3.57B on R&D in FY2025 (12.6% of revenue), among the highest absolute and relative spends in semicap. Because process development is shared across the broadest tool portfolio, Applied can co-optimize integrated solutions (e.g., deposition + selective etch + thermal for a GAA transistor) that single-lane competitors cannot — and it amortizes that spend over the largest revenue base in WFE. Smaller competitors cannot match the absolute dollars; equal-percentage spenders cannot match the breadth.

2. Customer captivity / switching costs. Once a tool is qualified into a customer’s process flow at a given node, switching vendors means re-qualifying — months of work, yield risk, and the chance of disrupting a high-volume line. This captivity is node-specific and strongest at the leading edge (where yield is fragile and the cost of a mistake is enormous) and weakest at trailing/ICAPS nodes (where processes are mature and second-sourcing is easier) — which is exactly why Applied’s defensibility is highest in leading-edge foundry-logic/DRAM and lowest in the Chinese ICAPS market.

3. Installed-base flywheel. 35,000+ AIx-connected chambers generate a growing AGS annuity and deepen the data/relationship advantage at each customer — each system sold today seeds years of service revenue and tightens the integration.

4. Co-development infrastructure. The new EPIC Center (a ~$4B Silicon Valley R&D platform unveiling October 2026, co-invested with customers/suppliers/government and with TSMC, Samsung, SK Hynix and Micron as named participants) institutionalizes early-stage co-development — locking Applied into customers’ roadmaps before a node is in production.

Where the moat is real — and where it is not. Applied is #1 or co-leader in deposition (CVD/PVD/ALD/epi), epitaxy, ion implant, thermal/RTP and CMP; it has taken conductor-etch share (Gartner-cited ~+300bps in CY2025, with Sym3 the fastest-ramping product in company history) and calls itself #1 in advanced packaging and in memory process equipment. But the moat is lane-uneven: Applied does not compete in lithography (ASML’s monopoly) and trails KLA in process control — a lane where a Morgan Stanley analyst flagged declining share (management disputed, citing cold-field-emission eBeam and optical-inspection gains). The honest read: Applied’s advantage is breadth and materials-engineering depth, not universal dominance.

The tool-by-tool competitive map clarifies exactly where the advantage lives:

(Source: FY2025 10-K Competition; Q2 FY26 call; industry share aggregators. Interpretation: Applied dominates the chemical/physical materials-engineering steps and is gaining in etch and packaging — the lanes where AI/3D content growth is fastest — while ceding patterning entirely and trailing in inspection.)

The competitive threat the bulls under-weight. The FY2025 10-K explicitly warns that export controls “may cause us to be displaced by foreign and Chinese domestic companies.” Subsidized Chinese toolmakers — NAURA (deposition/etch/thermal/clean), AMEC (etch), ACM Research (clean/plating), Piotech (deposition) — are taking Applied’s trailing-node CVD/PVD/etch/CMP/thermal lanes inside China, propelled by subsidies, a domestic-purchasing mandate, and the controls themselves. This is the structural reason Applied’s China revenue fell from 37% of total (FY24) to 30% (FY25) to ~24% of SSG+AGS (Q2 FY26). It is not yet a leading-edge threat — but it is a real, compounding erosion of roughly a quarter of revenue, and Applied discloses no leading-edge-vs-ICAPS China split to let investors size it precisely.

Share-stability and ROIC tests (Greenwald). On the ROIC test, Applied passes emphatically: ~40% ROE, ~35% segment operating margins, and a 50% gross margin rising with new-tool launches all indicate a genuine advantage being expressed in returns. On the share-stability test, the picture is mixed: stable-to-gaining at the leading edge (etch share up, GAA content gains), but losing share in the Chinese trailing-node market to domestic entrants. A moat that is widening where the highest-value spend is, and eroding where the lowest-value (and most geopolitically fraught) spend is.

Verdict (Competitive Position): DURABLE, BROAD ADVANTAGE at the leading edge; eroding at the Chinese trailing edge. The R&D-scale-plus-captivity-plus-breadth moat is real and visible in the returns, and it is widening exactly where AI capex is flowing (leading-edge logic, DRAM, packaging). The qualifier — Chinese domestic substitution in ICAPS — caps roughly a quarter of revenue and is the one place the moat is genuinely losing ground.

5. Growth History and Forward Opportunities

Historical growth. Applied has compounded revenue at a high-quality, mostly-organic rate through one full cycle: $17.2B (FY20) → $23.1B (FY21, +34%) → $25.8B (FY22, +12%) → $26.5B (FY23, +3%) → $27.2B (FY24, +3%) → $28.4B (FY25, +4%) — a ~10.5% five-year CAGR, with the FY23–FY24 “plateau” reflecting the memory-led WFE downturn that Applied weathered far better than memory-exposed peers (its foundry-logic and AGS mix cushioned the trough). The growth is overwhelmingly organic — Applied has made no transformative acquisition (the one attempt, Kokusai, was abandoned), so the revenue base reflects share gains and content growth, not roll-ups.

The FY26 inflection. Growth has re-accelerated sharply in FY2026 as AI capex flows into Applied’s strongest lanes. H1 FY26 revenue was $14.92B (Q1 $7.01B + Q2 $7.91B) vs ~$14.27B in H1 FY25; Q2 FY26 set a record at $7.91B (+11% YoY, +13% sequentially), and Q3 FY26 is guided to $8.95B ±$500M (+23% YoY) with non-GAAP EPS of $3.36 ±$0.20 (+36% YoY). Management guides the semiconductor-systems business to grow >30% in calendar 2026 (calendar 2026 = fiscal Q2-26 through fiscal Q1-27, which is a 14-week quarter), with a “similar profile” expected in 2027.

Forward opportunities — quantified where management has done so. The growth case rests on content gains at architectural inflections rather than unit volume:

• GAA logic ramp — content gains plus “multiple points of market-share gains,” driven by Trillium ALD and Precision PECVD.
• Advanced packaging >50% growth in CY2026, with the pending NEXX acquisition adding panel-level capability for larger AI-accelerator packages.
• DRAM share gains at 6F²→4F²→3D-DRAM inflections (Applied claims a path to ~+10 points of DRAM WFE share over ~a decade — an aggressive, unverified management target).
• AGS mid-teens growth (above its historical low-double-digit pace), boosted near-term by rising utilization and new-fab ramps; the most durable, least cyclical growth leg.
• ICAPS recovery — management expects ICAPS equipment to “eventually grow at the same rate the devices are, mid-to-high single digits,” once utilization catches up with installed capacity (a normalization, not a boom).

Quality of the growth. This is high-quality growth where it is leading-edge-driven: content gains at GAA/DRAM/packaging are sticky, high-margin, and tied to architecture transitions that recur every node — the gross-margin expansion to 50% confirms the growth is being priced, not bought. The lower-quality element is the cyclical and China-substitution overhang: a meaningful slice of the FY26 acceleration is the up-leg of a capital cycle, not pure secular compounding, and the ICAPS/China base that historically drove “volume” growth is structurally capped.

Verdict (Growth): HIGH-QUALITY at the core, cyclically-amplified at the margin. The content-gain growth at leading-edge logic, DRAM and packaging is genuine, margin-accretive and durable; the headline FY26 >30% systems growth is partly the cyclical up-leg and should not be extrapolated as a run-rate.

6. Financial Quality

Revenue and margins. Revenue compounded ~10.5%/yr over five years to $28.4B (FY25), with gross margin climbing from 44.7% (FY20) to 48.7% (FY25, GAAP) and 50.0% non-GAAP in Q2 FY26 — the highest in 25+ years. The driver, per management, is “value-based pricing from our most differentiated products coupled with manufacturing cost innovations” — i.e., genuine pricing power, corroborated by the new SSG segment gross margin of 54.8%. Operating margin is ~29% GAAP / ~32% non-GAAP and rising. These are exceptional margins for a capital-equipment business and are the clearest evidence the moat is real.

(Source: company filings reconciled to SEC EDGAR XBRL.)

The FY24-vs-FY25 net-income optical trap (quality-of-earnings flag #1). Note that GAAP net income fell from $7,177M (FY24) to $6,998M (FY25) despite revenue rising — a misleading optic. The cause is tax: FY24’s GAAP effective rate was an abnormally low ~12% ($975M on $8,152M pre-tax), versus FY25’s ~24.5% ($2,273M on $9,271M). Normalizing both to a mid-teens rate, pre-tax operating earnings grew, and FY25 net income would have grown ~double-digits. Applied’s normalized tax rate is low (management models ~11% non-GAAP for Q3 FY26, reflecting the Section 48D investment tax credit — raised from 25% to 35% under the 2025 OBBBA — and foreign mix); the GAAP rate is volatile year to year on discrete items. Implication: do not read the FY24→FY25 GAAP net-income decline as deterioration, and do not extrapolate any single year’s tax rate.

Earnings composition (quality-of-earnings flag #2). A growing slice of pre-tax income is non-operating, non-cash: the ~9% equity stake in BE Semiconductor (Besi), held as a marketable security and marked to market through other income, contributed ~$792M in FY25 and ~$1,138M in H1 FY26 (lifting H1 OI&E to ~$1,337M). This is a real economic gain but it is non-cash, mark-to-market, and reverses if Besi’s share price falls — it flatters reported net income and should be stripped when assessing operating earnings power. Combined with the low/volatile tax rate, reported EPS overstates the quality and stability of operating EPS.

Free cash flow and the capex step-up. FCF was $7.5B (FY24) but fell to $5.7B (FY25) even as operating cash flow stayed strong (~$8.0B) — because capex doubled from $1.19B to $2.26B, and is still climbing (H1 FY26 capex $1.28B vs $0.89B prior-year). This is the multi-year build-out of the EPIC Center (~$4B) and the new ~$500M Singapore (Tampines) campus announced June 2026. The spend is strategic (it deepens the co-development moat) but it is a genuine, multi-year drag on FCF conversion — FCF/NI fell from ~104% (FY24) to ~81% (FY25). Investors underwriting “100% FCF conversion” need to haircut for the build period.

Balance sheet. Pristine. FY25 cash + short-term investments ~$8.6B against ~$6.65B of senior notes (next maturity ~$750M in FY27) — net cash, with $4.1B of undrawn revolvers behind it. Inventory rose to $5.9B (FY25) and receivables have climbed (+~23% over two quarters to ~$6.4B at Q2 FY26) as revenue accelerated and China is ~27% of revenue — worth monitoring for collection/linearity risk, but not alarming at current utilization. SBC is modest at $668M (~2.4% of revenue), well below software/internet norms.

The AGS annuity — why it deserves a higher multiple than systems. A point under-appreciated in the headline numbers: Applied Global Services is a structurally better business than the systems segment, and it is growing. AGS revenue compounded from $5.73B (FY23) to $6.39B (FY25) and hit a $1.67B quarterly record in Q2 FY26 (+17% YoY), at ~28–29% operating margins, driven by factory utilization (an installed-base metric) rather than new-capacity decisions — so it falls far less in downturns and provides a cyclical shock-absorber. The installed base of 35,000+ AIx-connected chambers is a compounding asset: each new system sold today seeds years of high-margin spares, service and software, and the more chambers running, the larger and stickier the annuity. Management’s push toward subscription agreements (still partly aspirational) and its raised mid-teens growth target would, if delivered, gradually de-cyclicalize the consolidated model. The caveat: at ~23% of revenue, AGS is not yet large enough to dominate the cycle — Semiconductor Systems (73%) still sets the amplitude — but it is the single most important reason Applied’s trough earnings are higher-quality than a pure equipment vendor’s.

Working capital and the China receivables watch-item. As revenue re-accelerated, receivables climbed ~23% over two quarters to ~$6.4B (Q2 FY26) and inventory sits at ~$5.9–6.3B. At current full utilization this is normal scaling, but with China ~27% of revenue and trailing-node demand the softest part of the book, receivables linearity and collection are worth monitoring — a sharp China step-down could leave inventory and receivables stranded, the classic way a cyclical’s working capital turns from tailwind to headwind at the top. No evidence of stress today; flagged as a forward watch-item.

Returns. ROE ~40%, ROIC comfortably above cost of capital (management’s own LTI plan is anchored on non-GAAP economic profit, i.e., ROIC-minus-WACC). These are high-return-on-capital characteristics that pass the Greenwald ROIC test for a genuine moat. To put the margin structure in peer context: Applied’s ~50% non-GAAP gross margin now sits roughly in line with Lam (~50%) and below KLA (mid-60s, reflecting KLA’s software-like inspection franchise) and ASML (~52%), while its ~32% non-GAAP operating margin is comparable to Lam’s ~35% and below KLA’s ~40%+. Applied earns slightly lower margins than the most specialized peers — the price of breadth and a larger, lower-margin AGS/ICAPS mix — but on a far larger revenue base, and the trajectory (up ~800bps of gross margin since 2013) is the relevant signal.

Verdict (Financial Quality): EXCELLENT operating economics; reported EPS modestly lower-quality than it looks. Margins are rising, returns are high, the balance sheet is net cash, and cash conversion is strong ex-the-build. The two yellow flags — a low/volatile tax rate and a growing non-cash Besi mark in reported earnings — mean operating EPS is somewhat lower and steadier than reported EPS; normalize both before valuation.

7. Capital Allocation

Philosophy. Applied runs a disciplined, returns-oriented, net-cash capital-allocation model: fund organic R&D and strategic capex first, return essentially all remaining free cash flow via buybacks and a growing dividend, and avoid large, dilutive M&A. The record supports the description.

Shareholder returns. The dividend was raised 15% to $0.53/quarter in March 2026 (the eighth consecutive double-digit raise, completing a multi-year “double the dividend” goal), an annualized $2.12 — only ~1.1% yield on a $499 stock, but a low ~20% payout that leaves ample room to grow. Buyback authorizations total $20B ($10B in March 2023 + $10B in March 2025), with $13.2B remaining at April 2026. Repurchases have accelerated: $2.19B (FY23) → $3.82B (FY24) → $4.90B (FY25). Total FY25 returns of ~$6.28B were ~110% of FCF, part-funded from the cash pile. Diluted share count has fallen from ~919M (FY21) to ~799M (Q2 FY26) — a ~13% reduction — genuinely deleveraging the share count from cash flow, not debt.

M&A discipline. The defining episode is the Kokusai Electric deal: announced in 2019 at ~$2.2B, Applied terminated it in March 2023 after failing to clear Chinese (SAMR) antitrust before the outside date — walking away rather than litigating or overpaying. Beyond that, only immaterial tuck-ins (~$29M in FY25) and the pending NEXX panel-level packaging acquisition. The ~9% Besi stake is a low-risk optionality play on hybrid bonding (held as a marketable security, now a large paper gain), not a control deal. The growth has been built organically through R&D — a point firmly in management’s favor and a contrast to acquisition-driven peers.

The capex question. The one place to push back is the capex step-up — doubling to $2.26B (FY25) and rising — to fund EPIC (~$4B) and Singapore (~$500M). The strategic logic is sound (co-development infrastructure deepens the moat and pulls customers onto Applied’s roadmap early), but it compresses near-term FCF conversion and the returns on this internal capex are harder to verify than a buyback. We judge it reasonable given the franchise, but it is the swing factor in FCF for the next 2–3 years.

Incentive alignment. CEO Gary Dickerson’s FY25 total direct compensation was $29.5M, of which ~96% is variable and ~91% equity. Crucially, the long-term incentive metrics are high-quality: non-GAAP economic profit (an EVA/ROIC-vs-WACC measure), relative TSR, gross/operating margin, and WFE market share — and from FY25, 50% of PSUs are tied to a 3-year economic-profit target. The FY25 annual bonus paid below target, and say-on-pay passed at 91% (2025). Governance is clean (double-trigger change-in-control, no pensions or excise-tax gross-ups). This is a genuinely well-aligned, returns-anchored pay structure — management is paid to grow economic profit and share, not just revenue.

Insider behavior. Trailing-six-month Form 4 activity shows codes S/A/G/F only — zero open-market purchases (code P). The CFO and a director sold; the CEO’s transactions were tax-withholding (F) only. The signal is neutral-to-mildly-negative — routine sales, no conviction buying — consistent with a richly-valued stock; not a red flag, but not a vote of insider confidence at $499 either.

Verdict (Capital Allocation): STRONG and disciplined. Net cash, low-payout-but-fast-growing dividend, large buyback dry powder, steady share-count reduction, organic-only growth with one walk-away from a deal that wouldn’t clear, and EVA/ROIC-anchored, heavily at-risk pay. The only caveats are the FCF-compressing capex build and the absence of insider buying at the current multiple — neither a thesis-breaker.

8. Changes and Headwinds — Last Two Years

Strategic / positive.

• AI-driven mix shift toward leading-edge foundry-logic, DRAM and advanced packaging — Applied’s strongest, highest-margin lanes — driving record revenue, a 50% gross margin, and a >30% CY2026 systems-growth guide.
• Segment-margin transparency: from Q1 FY26 Applied now discloses segment-level gross margin (SSG 54.8%), letting investors see the pricing power directly; the 200mm business was recast from AGS into SSG.
• EPIC Center (~$4B Sunnyvale co-development platform) unveiling October 2026, and a $500M Singapore campus (June 2026, +1,000 jobs) — multi-year capacity/co-development investments.
• NEXX acquisition (panel-level packaging) and continued Besi hybrid-bonding collaboration — positioning for advanced-packaging growth.
• Capital-return milestones: 15% dividend raise (March 2026), $10B buyback top-up (March 2025).

Headwinds / negative.

• China: revenue down from 37% (FY24) to 30% (FY25) to ~24% of SSG+AGS (Q2 FY26) as export controls and domestic substitution bite; ICAPS worldwide guided only “flat to slightly higher” in CY2026.
• Export-controls / legal: multiple DOJ, BIS and SEC subpoenas since 2022 regarding China shipments and export-controls compliance, and a ~$253M settlement charge (a previously-disclosed BIS export-controls matter, paid in Q2 FY26) that pressured SSG margins in H1 FY26.
• Capex-driven FCF compression (FCF/NI from ~104% to ~81%) during the EPIC/Singapore build.
• Valuation re-rating: the stock has re-rated to the 99.9th percentile of its own ten-year multiple history, raising the bar for forward returns (see the Valuation section).
• News tape (June 2026): quiet and skewed positive — the most material recent item is the Singapore campus announcement (Benzinga, 2026-06-10, scored positive). No negative thesis-changing headline in the recent feed.

Verdict (Changes): NET STRENGTHENING of the operating thesis, NET TIGHTENING of the risk/reward. The business is executing into the best demand environment in its history with its mix shifting to its best lanes; the offsets are the structural China erosion, the export-controls overhang, and a valuation that has already priced much of the good news.

9. Risk Analysis (Risk Matrix)

The two risks that actually decide the outcome. Of the eleven rows above, two are first-order and the rest are second-order. The first is the interaction of the cyclical-downturn risk with the multiple-de-rating risk — they are not independent. A WFE downturn would compress both earnings and the multiple simultaneously (the “double-count” working in reverse), which is precisely why cyclicals at peak multiples on peak earnings are dangerous: the two factors multiply rather than add. The base-rate is sobering — the last WFE trough (FY23–24) was only ~24 months ago, and memory makers cut capex 40–50% within it. The bull’s entire case rests on the proposition that AI has changed the base rate; if it hasn’t, the downside is the bear scenario, not the base.

The second is China’s structural erosion (high-likelihood, medium-impact), which is the more insidious because it is gradual and partly irreversible. Unlike a cyclical dip (which recovers), the in-sourcing of Applied’s trailing-node lanes by subsidized domestic competitors is a one-way ratchet — every chamber NAURA or AMEC qualifies into a Chinese fab is a chamber Applied likely never sells again. The export-control regime makes this worse by forcing localization. Applied does not disclose the leading-edge-vs-ICAPS China split, so investors cannot size precisely how much of the ~24–30% China base is genuinely defensible. Our interpretation: roughly half of China revenue (the more leading-edge-adjacent portion) is reasonably defensible near-term, and the trailing-node remainder is on a multi-year decline — a slow, compounding drag of perhaps 1–3 points of total revenue per year if the trend holds.

The remaining risks — customer concentration, process-control share loss, capex/EPIC execution, earnings-quality reversal — are real but manageable and unlikely to be thesis-breaking on their own. The technology-roadmap-misstep and Taiwan-geopolitical risks are low-probability/high-impact tails: a missed node inflection would slowly cede content to Lam/TEL (the moat erodes rather than collapses), while a cross-strait event would be catastrophic for all WFE, not Applied specifically — an un-hedgeable, un-diversifiable tail that argues for position-sizing discipline rather than avoidance.

Catastrophic-loss assessment. The probability of permanent capital impairment from a business failure is low: Applied is net cash, profitable through cycles, and structurally entrenched. The realistic downside is valuation-driven (a multiple reset on a cycle turn) plus a tail geopolitical scenario (Taiwan/China). A total loss is implausible absent a systemic geopolitical rupture.

10. Valuation Discussion (Embedded Expectations)

No price target and no recommendation. This section frames what the current price implies and tests it against scenarios.

Where the multiple sits. At $499.21 (2026-06-09), AMAT trades at ~$396B market cap / ~$392B EV (net cash). On trailing GAAP earnings (~$10.6 TTM EPS) that is ~47× P/E; on forward (FY27) consensus it is ~31×; ~13.6× EV/sales; ~16.7× book; ~42× EV/EBITDA. The single most important valuation fact: on Applied’s own ten-year history, P/E, P/B and P/S are each at the ~99.9th percentile — a stock that spent most of the last decade at 12–18× earnings now trades at 47× trailing. The earnings to which this peak multiple is applied are, by management’s own account, running with “most leading-edge logic and DRAM fabs at full capacity.”

The cross-sectional paradox. Yet against its peers, AMAT is the cheapest WFE major:

(Source: market data providers, 2026-06-09 — reconciled to filings; ASML EV/EBITDA distorted by a data artifact.)

AMAT’s ~30% discount to Lam/KLA on forward P/E is the bull’s central argument, and it is partly justified: Applied’s larger, lower-multiple AGS and ICAPS mix, its bigger (declining) China exposure, and its lower revenue-growth print (+11% YoY vs Lam’s +24%) all argue for some discount. The question is whether ~31× forward / 47× trailing is “cheap” in any absolute sense, or merely “the least expensive ticket in an expensive theatre.” We read it as the latter — the discount is real but the absolute multiple still embeds a benign cycle.

Embedded-expectations analysis. To support a ~$392B EV on ~$29B TTM revenue and ~$8–9B operating income, the market must be underwriting, roughly: (a) WFE growing 20–30% in 2026 and another record in 2027 with no deep digestion thereafter; (b) Applied’s systems business compounding low-double-digits beyond the cycle via GAA/DRAM/packaging content gains; © China troughing and stabilizing (not structurally collapsing); (d) AGS compounding mid-teens; and (e) the multiple staying well above the historical average. In plain terms: the price assumes AI capex has substantially de-risked the WFE cycle and that Applied holds a premium multiple through it. Each individual assumption is defensible; the joint probability — peak cycle, peak multiple, China stabilizing, all simultaneously — is what the bull case requires and what we think is mispriced.

Scenario analysis (3-year, to ~mid-2029). Illustrative, on normalized non-GAAP EPS (stripping the Besi mark, normalizing tax to ~13%). FY26 normalized non-GAAP EPS ~$13; the cases vary the cycle path and the exit multiple:

(Assumptions explicit; not a forecast. The point is the shape: even the base case — where earnings grow ~40% over three years — returns roughly zero because the multiple de-rates from the 99.9th percentile, and the bear case is a 50%+ drawdown. Only the uninterrupted super-cycle pays, and even then modestly.) The skew is negatively asymmetric: you are paid little for the cycle continuing and punished heavily if it turns.

A reverse-DCF sanity check. Approached from the other direction: to justify ~$392B EV at a ~9% discount rate and a terminal ~18× exit on FCF, Applied must grow free cash flow at roughly low-double-digits annually for a decade with no multi-year interruption — i.e., the ~$5.7B FY25 FCF (or ~$7.5B normalized for the capex build) compounding to ~$15–18B by the mid-2030s. That is achievable if WFE roughly doubles and Applied’s content gains hold, but it leaves no margin for a cyclical air-pocket: a single down-cycle that cuts FCF 25–30% (as FY23–24 did to memory peers) resets the compounding base and, combined with multiple normalization, is what produces the bear outcome. The price is not “expecting a disaster”; it is “expecting the cycle never seriously interrupts” — a high bar for a business whose entire history is cyclical.

Why the peer discount does not rescue the absolute call. The bull leans on AMAT’s ~30% forward-P/E discount to Lam/KLA. But three of the reasons for that discount are structural, not temporary: (1) a larger AGS/ICAPS/200mm mix that is lower-multiple than pure leading-edge tools; (2) the biggest China exposure of the majors, which is eroding; and (3) the slowest revenue-growth print of the group (+11% YoY vs Lam +24%). A discount that exists because of permanent mix and growth differences will not necessarily close — and even if AMAT re-rated all the way to Lam’s ~41× forward, it would be re-rating toward a peer that is itself at its own 99.9th percentile. “Cheap relative to something even more expensive” is not a margin of safety.

The own-history anchor. Applied’s ten-year average P/E is roughly 17–18×; even a re-rating merely toward (not to) that average, applied to higher-but-cyclical earnings, produces flat-to-negative returns over a multi-year hold. The bull must believe the historical multiple range is obsolete — that AI has permanently re-rated WFE. That is possible; it is also exactly the belief that defines a late-cycle top. The cleanest way to hold the position: the business merits a structurally higher multiple than its 12–18× history (the moat is wider, the margins higher, AGS larger, capital allocation better) — but “structurally higher” plausibly means low-20s×, not 47× trailing on cyclical-peak earnings. The gap between a defensible ~22× and today’s ~31× forward / 47× trailing is the embedded optimism.

Verdict (Valuation): a high-quality franchise at a price that embeds a benign cycle. Cross-sectionally the cheapest WFE major; on its own history, priced for perfection on near-peak earnings. The asymmetry is unfavorable: the base case returns little, the bear case hurts, and only the super-cycle rewards.

11. Variant Perception

Consensus view. The sell-side is broadly constructive (aggregated analyst rating ~4.5/5, average target ~$510). The consensus narrative: Applied is a premier “AI picks-and-shovels” compounder whose mix has decisively shifted to the best parts of WFE (leading-edge logic, DRAM, packaging), with a 50% gross margin proving pricing power, mid-teens AGS growth de-cyclicalizing the model, and a valuation discount to Lam/KLA that should close. In this view the cycle has been substantially de-risked by a multi-year AI build, and AMAT is the cheapest way to own it.

Strongest bull case. (1) AI infrastructure is a genuine multi-year capex super-cycle, and >80% of its WFE growth lands in Applied’s strongest lanes. (2) Content-per-wafer gains at GAA/DRAM/packaging mean Applied’s served market grows faster than WFE, with share gains on top. (3) The 50% gross margin and EVA-anchored management signal a structurally higher-return business than the historical multiple reflects. (4) At ~31× forward, AMAT is ~30% cheaper than Lam/KLA — a re-rating up toward peers is plausible if execution continues. (5) Net cash, ~100%+ FCF return, and double-digit dividend growth provide a floor.

Strongest bear case. (1) Peak-on-peak: a 99.9th-percentile own-history multiple on earnings management itself describes as running at full fab utilization — the textbook cyclical trap. (2) China is structurally eroding (37%→30%→24%), not merely cyclically soft, as controls + subsidized domestic toolmakers in-source Applied’s trailing-node lanes; ICAPS guided only flat-to-slightly-up. (3) Earnings quality: reported EPS is flattered by a low/volatile tax rate and a large non-cash Besi mark. (4) Legal/geopolitical overhang: $253M BIS settlement, serial subpoenas, and a Taiwan-concentration tail. (5) Insiders are selling, not buying, at the multiple. (6) The cycle has not been abolished — the last WFE trough was ~24 months ago.

The 3–5 assumptions that matter most:

1. Does the AI-capex cycle digest in the next 2–3 years? (Bull: no/shallow. Bear: yes/sharp.) — the single biggest swing factor.
2. Does China revenue stabilize or keep eroding? (~a quarter of revenue.)
3. Does the multiple hold above ~25×, or revert toward the ~17× historical mean?
4. Do GAA/DRAM/packaging content gains actually compound the served market faster than WFE?
5. Is normalized operating EPS (ex-Besi, normal tax) materially below reported EPS?

Falsifying evidence. Bull falsified by: a WFE down-year (memory/AI digestion) printing while the multiple is still >35×; China revenue stepping down another tier; a GAA/DRAM content-gain miss ceding share to Lam/TEL. Bear falsified by: WFE growing through 2027–28 with no digestion, China stabilizing at ~20%+ of revenue, AGS sustaining mid-teens growth, and the multiple holding — i.e., genuine evidence the cycle has de-risked.

Our read. The bull is right about the franchise and right that AMAT is the cheapest major; the bear is right about the cycle and the multiple. The variant perception worth holding: the market is correctly pricing Applied’s quality and relative cheapness but is under-pricing the cyclicality and the China structural erosion — so the peer discount is real but insufficient compensation for buying near-peak earnings at a near-peak own-history multiple.

12. Fact vs. Interpretation

13. Open Questions

1. What is Applied’s leading-edge-vs-ICAPS split within China? The 10-K does not disclose it, leaving investors unable to size the trailing-node substitution risk precisely.
2. How much of FY26 systems growth is cyclical vs. secular content gain? Management blends them; the durable run-rate is the key unknown.
3. What is normalized operating EPS stripped of the Besi mark and at a normal tax rate — and how far below reported EPS?
4. Will the export-controls regime tighten further, and what is the residual legal exposure beyond the $253M settlement?
5. What ROI will the ~$4B EPIC + $0.5B Singapore capex earn, and when does FCF conversion normalize?
6. Can Applied actually gain ~10 points of DRAM WFE share over a decade as it claims, against Lam/TEL?
7. Where does WFE go in 2028 — does the AI build digest, and how sharply?

14. What Must Be True

For the bull case to win (long thesis):

• WFE grows through 2027–2028 with no deep digestion — AI capex genuinely flattens the cycle. Falsification test: a printed WFE down-year (or two consecutive down-quarters of customer capex guidance) while the multiple is still >35× falsifies it.
• Applied’s content gains at GAA/DRAM/packaging compound its served market faster than WFE, with share gains. Falsification test: SSG growth lagging total WFE growth for a full year, or a Gartner/TechInsights share-loss print in etch/deposition, falsifies it.
• China stabilizes at ~20%+ of revenue rather than eroding further. Falsification test: China falling below ~20% of SSG+AGS with ICAPS still soft falsifies it.
• The multiple holds above ~25×. Falsification test: a de-rating toward the ~17× historical mean (even on flat earnings) falsifies the return case.

For the bear case to win (avoid/caution thesis):

• The cycle turns within 2–3 years (memory/AI-capex digestion), or China steps down structurally, while the multiple is still elevated. Falsification test: WFE up every year through FY28, China stable at 20%+, AGS sustaining mid-teens, and the multiple holding — i.e., the franchise grows into the price — falsifies the bear.
• Normalized operating EPS proves materially below reported EPS (Besi/tax). Falsification test: Besi mark reversing harmlessly and the tax rate proving structurally low (not volatile) falsifies this leg.

The crux: both cases agree the franchise is excellent and the relative multiple is the cheapest in the group. They disagree only on whether the absolute multiple on cyclical-peak earnings, with China eroding, adequately compensates a buyer at $499. That single question — has AI de-risked the WFE cycle? — decides the outcome.

15. Source Appendix

See Appendix B below for the full, categorized source list with URLs and access dates. Primary sources: Applied Materials FY2025 Form 10-K (filed 2025-12-12, accn 0001628280-25-056742); Q2 FY26 Form 10-Q (filed 2026-05-21, accn 0001628280-26-037227); Q1/Q2 FY26 earnings-call transcripts (2026-02-12, 2026-05-14); DEF 14A proxy; Form 4 filings; SEC EDGAR XBRL (CIK 0000006951). Market data: public market-data providers and aggregated fundamentals/news/transcripts (accessed 2026-06-10). Frameworks: Greenwald & Kahn, Competition Demystified; Marathon Asset Management, Capital Returns.

This article is independent research for general information only and is not investment advice. Sections 1–15 carry no recommendation and no price target; the Claude’s Take block is the author’s own separately-labeled subjective view.

APPENDIX A — Standard Diligence Questionnaire

Applied Materials, Inc. (NASDAQ: AMAT) — as of 2026-06-10

Answers labeled Fact / Interpretation / Assumption where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions: (1) Has AI capex structurally de-risked the WFE cycle, or is this just a bigger version of the same cycle? (2) How much of China’s ~30% revenue base is permanently lost to export controls + domestic substitution? (3) Why does AMAT trade at a ~30% discount to Lam/KLA — and does that gap close up or is it deserved? (4) How much of reported EPS is “real” operating earnings vs. the non-cash Besi mark and a low tax rate? (5) Can AMAT actually take the DRAM/etch share it claims at GAA/3D-DRAM inflections? (6) What is the ROI on the ~$4B EPIC capex build?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Near a cyclical high. Management describes “most leading-edge logic and DRAM fabs running at full capacity,” gross margin at a 25-year high (50%), and Q3 guided +23% YoY. Fab utilization “can’t get much higher” is a peak signal.

Driven by external environment or internal actions? Both. External: the AI-capex super-cycle lifting WFE 20–30%. Internal: genuine mix-shift execution (content gains at GAA/DRAM/packaging) and value-based pricing driving the margin to 50%. The margin gains are internal/durable; the volume surge is largely external/cyclical.

How stable are revenues? Moderately cyclical. The ~23% AGS services annuity and foundry-logic mix cushion troughs (FY23–24 plateau was mild vs. memory peers), but Semiconductor Systems (73%) swings with customer capex. Not a smooth compounder.

Outlook for products/services? Strong near-term: systems +>30% CY2026, AGS mid-teens, packaging +50%, 2027 “another record year.” Longer-term hinges on the cycle durability (open question).

How big will this market be? WFE ~$135–140B (2026), record ~$156B+ semi-equipment (2027), growing; Applied’s served sub-segments (deposition/etch/implant/CMP/packaging) growing faster than WFE as devices go 3D. Predominantly international (China/Korea/Taiwan/US/Japan/Europe). Growing.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Mixed. At the leading edge, less competitive (consolidated oligopoly, rational pricing, rising margins). In the Chinese trailing-node (ICAPS) market, more competitive (subsidized NAURA/AMEC/ACM/Piotech in-sourcing AMAT’s lanes).

How profitable is the business (ROIC, ROE)? Very. ROE ~40%; segment operating margins ~35% (SSG) / ~29% (AGS); gross margin 50% non-GAAP; ROIC comfortably above WACC (management’s own LTI metric). Passes the Greenwald ROIC test.

How profitable is the industry — competitors, barriers? Among the most profitable in technology. ~5 vendors control 65%+ of front-end; barriers are formidable (multi-year qualification, decades of process IP, ~$3.6B/yr R&D, installed-base flywheel). Near-monopoly by tool type.

Can the business be easily understood? Reasonably — “the broadest maker of the tools that build chips.” The complexity is in the cycle, the China geopolitics, and the process-step competitive map.

Can it be undermined by foreign low-cost labor? Not by labor — by subsidized foreign capital + IP catch-up in China. This is real in trailing-node ICAPS, not (yet) at the leading edge.

Do brands matter? Not consumer brands; reputation + installed base + qualification status are the equivalent — extremely sticky at the leading edge.

Nature of competition? Technology/performance and co-optimization, not price — within each lane, vendors compete on enabling the customer’s next node, and incumbents rarely attack each other’s strongholds. Price competition is largely confined to Chinese trailing-node substitution.

Customers’ switching costs? High at the leading edge (requalification = months + yield risk); lower at trailing/ICAPS nodes — the asymmetry that defines where AMAT’s moat holds.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The ~9% Besi stake (marketable security, large paper gain), decades of process IP/know-how (expensed R&D), and the installed-base service annuity (off-balance-sheet economic asset). Interpretation: economic value materially exceeds book.

Off-balance-sheet liabilities? Nothing unusual — standard operating leases, purchase commitments; the export-controls legal exposure is the contingent item (a $253M settlement already taken; residual uncertain).

How conservative is the accounting? Mostly conservative (R&D expensed, modest SBC at ~2.4% of revenue). Two flags lowering earnings quality (not integrity): a low/volatile GAAP tax rate and a large non-cash Besi mark-to-market in other income.

How CapEx-hungry is the business? Historically light (~3–4% of revenue), now elevated (~8%, capex doubled to $2.26B) during the EPIC + Singapore build — a multi-year FCF drag, then a likely normalization.

Capital Allocation & Management

How much FCF, and how is it used? ~$5.7B FY25 FCF (~$7.5B ex the capex step-up). Used for buybacks ($4.9B FY25) and dividends ($1.38B), totaling ~110% of FCF; philosophy is organic-growth-first, then return ~all excess. Net cash.

Significant acquisitions recently? No transformative deals; the Kokusai (~$2.2B) attempt was terminated in 2023 (China antitrust) — a discipline positive. Pending small NEXX (packaging) tuck-in; Besi stake is a collaboration, not control.

Buying back shares? Yes, materially — $20B authorized, $13.2B remaining; share count 919M→799M.

Issuing large amounts of stock to insiders? No — SBC modest (~2.4% of revenue); net share count falling.

Compensation policy? CEO FY25 ~$29.5M, ~96% variable/~91% equity, anchored on non-GAAP economic profit (EVA/ROIC-vs-WACC), relative TSR, margin and WFE share. Say-on-pay 91%. Well-aligned; FY25 bonus paid below target.

Motivations of management? Returns- and share-gain-driven per the incentive design. Note: recent insider Form 4s show routine sales, no open-market buys — neutral-to-mildly-negative conviction signal at the current price.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — ordinary US common stock (NASDAQ: AMAT), 1099 reporting.

Dividend policy? Quarterly $0.53 (raised 15% Mar-2026), ~1.1% yield, ~20% payout, eighth straight double-digit raise. Growing but small relative to buybacks.

How profitable is the business? Highly — see above (50% GM, ~32% non-GAAP OM, ~40% ROE).

Is net income diverging from cash from operations? OCF ($7.96B FY25) exceeds NI (~1.14×) — healthy at the operating level. The divergence is at FCF (capex doubled) and in earnings composition (non-cash Besi mark + low tax rate flatter NI). Net: cash generation is genuine; reported NI is slightly lower-quality than headline.

Risks & Downside

What would cause the stock to decline? (1) A WFE cyclical turn (AI-capex digestion / memory glut); (2) multiple de-rating from the 99.9th own-history percentile; (3) a China revenue step-down; (4) export-controls escalation / new legal exposure; (5) a technology-roadmap miss at a node inflection.

Risk of catastrophic loss? Low from the business (net cash, profitable, entrenched). The genuine tail is geopolitical — a Taiwan/China rupture (Taiwan ~24% of revenue, TSMC the anchor customer) would be severe for all WFE.

Chance of total loss? Negligible absent a systemic geopolitical event. The realistic downside is a valuation-driven drawdown (the bear scenario ≈ -50%), not impairment.

Recent News & Events

Has the business environment changed recently? Yes, favorably on demand: AI capex has shifted WFE spending into AMAT’s strongest lanes (leading-edge logic, DRAM, packaging = >80% of 2026 WFE growth), driving record revenue and a 50% margin. Unfavorably on China (revenue 37%→24%) and legal (export-controls settlement).

Significant acquisitions? Pending NEXX (panel-level packaging); no large deals.

Change in accounting policies? Q1 FY26 recast of the 200mm business from AGS into SSG, and new segment-level gross-margin disclosure — presentational, not a policy red flag.

Recent changes — new markets, facilities, management? New $500M Singapore (Tampines) campus (June 2026, +1,000 jobs); EPIC Center (~$4B Sunnyvale) unveiling Oct 2026; 15% dividend raise (Mar 2026); $10B buyback top-up (Mar 2025). Management stable (CEO Gary Dickerson since 2013).

APPENDIX B — Source Appendix

Applied Materials, Inc. (NASDAQ: AMAT) — sources & evidence trail (as of 2026-06-10)

All non-obvious facts in this article trace to a public source below. Primary sources first; third-party data labeled and reconciled to primary where possible.

1. Primary — SEC filings (EDGAR, CIK 0000006951)

All filings are publicly available on SEC EDGAR.

2. Primary — Earnings calls & investor events

3. Quantitative data feeds (third-party — reconciled to filings)

4. Industry / market data

5. Frameworks

Methodological note: third-party aggregated figures treated as convenience data and reconciled to SEC filings for all material numbers. Management commentary (transcripts) is treated as hypothesis and validated against filings and financials. This article is position-agnostic and is independent research.